Jan 17 2020: GMV announced to the market that clinical trials were complete for NMPA.
Yacov is quoted saying "the company will shortly lodge the required documentation to the regulator and we are confident that NMPA approve will be received towards the middle of the year."
This link is from a site with the word stock and head in its name, so it might not show up here.
In the same article, an analyst is skeptical, calling it "a bit spivvy."
https://unauthorised investment advice/health/biotech-gmv-finishes-trial-needed-to-enter-chinese-market-shares-rally/
(The data was never lodged. A few months later, GMV officially denied it would delist from ASX, and promptly delisted.)
- Forums
- ASX - By Stock
- GMV
- GMVD Nasdaq
GMVD Nasdaq, page-189
-
- There are more pages in this discussion • 639 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online